| 2026-07-30 | Press release | Press release · Q2 2026 · Jul 2026 |
| 2026-07-30 | Deck | Earnings presentation · Q2 2026 · Jul 2026 |
| 2026-07-30 | Press release | Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress |
| 2026-07-30 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-30 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-30 | Transcript | Q2 FY26 earnings call transcript |
| 2026-07-16 | Press release | Press release · Q2 2026 · Jul 2026 |
| 2026-07-16 | Press release | Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results |
| 2026-07-15 | Press release | Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Diseas |
| 2026-06-24 | Deck | ALN-6400 An Investigational RNAi Therapeutic Targeting Plasminogen to Address Rare Bleeding Disorders · Q1 2026 |
| 2026-06-12 | Press release | Alnylam to Host Tenth “RNAi Roundtable” Webcast Series |
| 2026-06-03 | Press release | Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics |
| 2026-05-27 | 8-K | Form 8-K, Item 5.02 |
| 2026-05-15 | ESG report | Investor document · FY 2025 · May 2026 |
| 2026-05-12 | Press release | New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a |
| 2026-05-12 | Press release | New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a |
| 2026-05-07 | Press release | Alnylam to Webcast Presentations at Upcoming Investor Conferences |
| 2026-05-04 | Press release | Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM |
| 2026-05-04 | Press release | Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM |
| 2026-04-30 | Press release | Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress |
| 2026-04-30 | Press release | Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress |
| 2026-04-30 | Deck | Earnings presentation · Q1 2026 · Apr 2026 |
| 2026-04-30 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-30 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-06 | Proxy | Proxy statement · Apr 2026 |
| 2026-04-06 | Proxy | Definitive proxy statement |
| 2026-03-31 | Annual report | Annual report · FY 2025 · Mar 2026 |
| 2026-03-24 | Deck | Investor document · Mar 2026 |
| 2026-03-04 | 8-K | Form 8-K, Item 5.02 |
| 2026-02-13 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-12 | Press release | Press release · Q4 2025 · Feb 2026 |
| 2026-02-12 | Deck | Earnings presentation · FY 2025 · Feb 2026 |
| 2026-02-12 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-12 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-01-12 | 8-K | Form 8-K, Item 2.02 results |
| 2025-12-11 | 8-K | Form 8-K, Item 8.01 |
| 2025-12-03 | 8-K | Form 8-K, Item 5.02 |
| 2025-10-30 | Press release | Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress |
| 2025-10-30 | Deck | Earnings presentation · Q3 2025 · Oct 2025 |
| 2025-10-30 | 8-K | Form 8-K, Item 2.02 results |